Sernova Biotherapeutics Sees Potential in T1D Trial Results

Sernova Biotherapeutics Inc, a company focusing on therapies for type 1 diabetes (T1D), has released promising interim results from its phase 1/2 trial of the Cell Pouch Bio-hybrid Organ. The study involved 12 patients and showed successful islet engraftment and insulin production. Notably, 8 out of 12 patients achieved insulin independence, marking significant progress. The data also hinted at improved quality of life for participants, crucial for managing T1D.

Despite reducing the price target from CAD 1.90 to CAD 1.60 due to anticipated dilution, First Berlin Equity Research maintains a "Buy" rating. Sernova plans to initiate further trials in 2025 and 2026, including tests with Evotec's iPSC-derived clusters. The formation of a new clinical advisory board is expected to propel the T1D program forward, enhancing its credibility and appeal to investors and partners.